Table 2.
Patient survival by total and stratified analyses
| Subgroup | OS | PFS | RFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | HR (95% CI) | P | n | HR (95% CI) | P | n | HR (95% CI) | P | |
| Overall | 19 | 1.54 (1.01‐2.33)a | .044 | 5 | 0.92 (0.67‐1.26)a | .582 | 5 | 0.65 (0.29‐1.48)a | .307 |
| Ethnicity | |||||||||
| Caucasian | 7 | 0.94 (0.46‐1.91)a | .862 | 1 | – | – | 4 | 0.74 (0.28‐2.01)a | .559 |
| Asian | 12 | 2.19 (1.27‐3.78)a | .005 | 4 | 0.82 (0.65‐1.02)a | .080 | 1 | – | – |
| Cancer type | |||||||||
| Lung | 3 | 3.09 (1.75‐5.46)b | <.001 | – | – | – | – | – | – |
| Gastric or Colorectal | 9 | 1.00 (0.67‐1.50)a | .992 | 4 | 0.95 (0.67‐1.33)a | .745 | – | – | – |
| Ovarian | 5 | 3.49 (0.47‐25.62)a | .220 | – | – | – | 4 | 0.43 (0.29‐0.66)a | <.001 |
| Others | 2 | 1.63 (0.40‐6.69)a | .498 | 1 | – | – | 1 | – | – |
| miRtype | |||||||||
| miR‐200a | 4 | 1.03 (0.28‐3.82)a | .961 | 1 | – | – | 1 | – | – |
| miR‐200b | 3 | 1.83 (0.44‐7.65)a | .406 | 2 | 0.79 (0.55‐1.14)a | .213 | – | – | – |
| miR‐200c | 8 | 2.25 (1.39‐3.64)a | .001 | 2 | 1.28 (0.79‐2.09)a | .314 | 2 | 1.20 (0.18‐8.09)a | .854 |
| miR‐429 | 3 | 0.69 (0.22‐2.17)a | .522 | – | – | – | 1 | – | – |
| miR‐141 | 1 | – | – | – | – | – | 1 | – | – |
OS, overall survival; PFS, progression‐free survival; RFS, recurrence‐free survival; HR, hazard ratio; CI, confidence interval.
a
The HRs and 95% CIs of analyzed studies were pooled by the random‐effects model if the P value for heterogeneity was <.10 or I 2 was >50%.
b
The HRs and 95% CIs of analyzed studies were pooled by the fixed‐effects model if the P value for heterogeneity was more than .10 or I 2 was <50%.